vimarsana.com
Home
Live Updates
FDA Grants Breakthrough Device Designation to Assay for ACR-368 in Ovarian Cancer : vimarsana.com
FDA Grants Breakthrough Device Designation to Assay for ACR-368 in Ovarian Cancer : vimarsana.com
FDA Grants Breakthrough Device Designation to Assay for ACR-368 in Ovarian Cancer
The FDA granted breakthrough device designation to the ACR-368 OncoSignature assay for the identification of patients with ovarian cancer who may derive benefit from the CHK1/2 inhibitor ACR-368.
Related Keywords
Peter Blume Jensen ,
Acrivon Oncosignature ,
International Federation Of Gynecology ,
Acrivon Therapeutics Inc ,
Acrivon Therapeutics ,
Acrivon Predictive Precision Proteomics ,
Accessed December ,
Ovarian Cancer ,
News ,
Prexasertib ,
The Acr 368 Oncosignature Assay ,